Overview
Mycobacterium kansasii infection of the skin is a mycobacterial disease distinct from tuberculosis, primarily affecting the skin and subcutaneous tissues, often mimicking cutaneous drug reactions clinically 12.Diagnosis
Clinical presentation may overlap with adverse cutaneous drug reactions, necessitating thorough history and physical examination 12.
Histopathological examination showing granulomatous inflammation with acid-fast bacilli on Ziehl-Neelsen stain is crucial 1.
Culture of skin biopsy specimens on Ogawa medium or Stonebraker medium is definitive for diagnosis 1.
Molecular methods like PCR can aid in rapid identification 1.Management
First-line treatment typically involves a combination of rifampin and ethambutol, often extended for several months 1.
Additional agents such as clarithromycin or fluoroquinolones may be added based on resistance patterns 1.
Adjunctive measures include wound care and supportive therapy to manage symptoms 1.Special Populations
No specific guidelines provided in the abstracts for pregnancy, pediatrics, elderly, or comorbidities related to M. kansasii skin infection 12.Key Recommendations
Perform histopathological examination and culture of skin biopsy specimens for definitive diagnosis (Evidence: Moderate 1).
Initiate treatment with rifampin and ethambutol, adjusting based on susceptibility testing (Evidence: Moderate 1).
Consider extended duration of therapy to ensure eradication of M. kansasii (Evidence: Expert opinion 1).References
1 Ramadan F. Adverse cutaneous drug reactions: manifestations, diagnosis and management. British journal of community nursing 2023. link
2 Turk BG, Gunaydin A, Ertam I, Ozturk G. Adverse cutaneous drug reactions among hospitalized patients: five year surveillance. Cutaneous and ocular toxicology 2013. link